



## Assessment of *Helicobacter pylori* Eradication Treatment on Platelet Count in Patients with Immune Thrombocytopenic Purpura

<sup>1</sup>Saman Hosseini and <sup>2</sup>Mir Behrad Khamesee

<sup>1</sup>Department of Mechanical Engineering, University of Toronto, Toronto, ON, Canada

<sup>2</sup>Department of Mechanical and Mechatronics Engineering, University of Waterloo, Waterloo, ON, Canada

**Key words:** Immune thrombocytopenic purpura, *Helicobacter pylori*, platelet count, eradication

**Abstract:** The impact of *H. pylori* eradication on the platelet count in patients with Immune Thrombocytopenic Purpura is controversial. In this clinical trial, the effects of HP eradication on platelet count was assessed and analyzed. Forty Iranian patients with ITP were assessed in two groups. One group was treated with amoxicillin, clarithromycin and omeprazole. The other group received similar amounts of placebo. The platelet counts were analyzed before treatment and during the first, second and third months after treatment. The mean platelet count before treatment in the intervention and control groups were,  $67.85 \times 10^3$  and  $69.4 \times 10^3$  mm<sup>3</sup>, respectively ( $p = 0.82$ ). In the third month after treatment, it was  $107.15 \times 10^3$  mm<sup>3</sup> in the intervention group and the  $71.15 \times 10^3$  mm<sup>3</sup> in the control group ( $p < 0.001$ ). Repeated measures analysis confirmed the positive effect of *H. pylori* eradication on platelet count ( $p = 0.007$ ). In this study, it was found that *H. pylori* eradication in patients with immune thrombocytopenic purpura induced a dramatic increase in platelets count.

### Corresponding Author:

Saman Hosseini

Department of Mechanical Engineering, University of Toronto, Toronto, ON, Canada

Page No.: 20-28

Volume: 17, Issue 2, 2022

ISSN: 1816-3319

International Journal of Tropical Medicine

Copy Right: Medwell Publications

## INTRODUCTION

*Helicobacter pylori* is a gram-negative microaerophilic bacterium that colonizes the stomach of more than half of the human population<sup>[1,2]</sup>. However, the prevalence of *Helicobacter pylori* worldwide is not homogeneous<sup>[3,4]</sup>. In Western countries, the prevalence of infection has decreased over the past few decades<sup>[5-6]</sup>, however, the rate of *Helicobacter pylori* infection in developing countries such as Iran has been reported to be about 80-90%<sup>[7-8]</sup>. *Helicobacter pylori* is the main cause of chronic active gastritis and ulcers of the stomach and duodenum. *Helicobacter pylori* is a contributing factor in

the development of gastric cancer and mucosa-associated lymphoid tissue lymphoma<sup>[1,2]</sup>.

Multiple diseases associated with platelet aggregation have been associated with *H. pylori* infection. For example, people infected with *H. pylori* are more likely to have a heart attack, coronary heart disease and stroke<sup>[10-15]</sup>. It has also been suggested that *H. pylori* may initiate Thrombotic Thrombocytopenic Purpura (TTP), inducing platelet aggregation through interaction with the Von Will ebrand factor<sup>[16]</sup>. It has also been hinted that the chronic consequences of *H. pylori* infection may be associated with Idiopathic Thrombocytopenic Purpura (ITP), known to eradicate the bacterium from the gastric mucosa in some patients with ITP<sup>[17-25]</sup>.

The causal relationship between *H. pylori* infection and ITP has been stipulated in studies that revealed improved platelet counts after eradication in infected patients<sup>[26]</sup>. The prevalence of *H. pylori* infection in patients with ITP has been systematically investigated. No differences have been discovered with the healthy general population matched by age and geographical area<sup>[27]</sup>. In contrast, a study from Colombia reported a very high prevalence of *H. pylori* infection in patients with ITP (90.6%), which significantly differing from controls (43.8%)<sup>[17]</sup>. Numerous studies in adults have demonstrated a positive effect of *H. pylori* eradication with triple standard treatment on platelet counts in patients<sup>[17-20,23,32-27]</sup>. Cohort studies in Japan and Italy have reported higher response rates than others countries<sup>[23,28,30,31]</sup>.

The association between *H. pylori* infection and ITP was first described in 1998, when an Italian group reported a significant increase in platelet count in 8 of 11 ITP patients in whom the bacterium had been eradicated. However, in subsequent reports the results were contradictory. Studies often included patients with mild thrombocytopenia who were not usually treated. Therefore, the role of *H. pylori* eradication in the management of patients with ITP requires further investigation<sup>[23,33,34]</sup>, nevertheless, there is growing evidence of an association between *H. pylori* eradication and platelet recovery in ITP patients<sup>[22,25,35-37]</sup>. Clear evidence of an association between *H. pylori* eradication and ITP is not yet available and there are many inconsistencies in the handful of conducted studies. Prior studies have suggested that additional and more comprehensive research is requisite in this field<sup>[40]</sup>.

Screening and eradicating *H. pylori* infection may be an easier and safer treatment option than suppressing the immune system or removing the spleen in patients with ITP<sup>[19,38]</sup>.

The British Society of Hematology now recommends screening and eradicating *H. pylori* as an ITP (Evidence Level III) treatment<sup>[39]</sup>. To date, no reports in regard to these patients have been published in Iran. Because local experiences are important and due to the potential regional variability in *H. pylori* strains, this study was devised and designed to evaluate the treatment of *H. pylori* eradication on platelet count in patients with immunosuppressive thrombocytopenic purpura.

## MATERIALS AND METHODS

**Immune Thrombocytopenic Purpura (ITP):** Immune thrombocytopenic purpura (also known as idiopathic thrombocytopenic purpura) is an acquired disorder characterized by immune-mediated platelet degradation and possibly inhibition of platelet release from megakaryocytes. In children, it is usually an acute illness

that most commonly occurs after an infection and has a self-limiting course, however, in adults it becomes more chronic. The exact nature of the immune dysfunction in this disease is not known. When ITP is related to an underlying disease, it is referred to as a secondary term. Common underlying disorders, in particular, can include immune disorders such as Systemic Lupus Erythematosus (SLE) and infections such as HIV and hepatitis C. The association of ITP with *H. pylori* is unknown.

Immune thrombocytopenic purpura is characterized by mucosal cutaneous bleeding and generally very low platelet counts while other peripheral blood cells and their smears are normal. Patients are usually admitted with eczema and petechiae, or their thrombocytopenia is accidentally detected in a comprehensive blood cell test. In these patients, mucosal cutaneous bleeding such as bleeding from the oral mucosa, gastrointestinal tract or heavy bleeding during menstruation may occur. In rare instances, life-threatening hemorrhages may also occur in the central nervous system. Wet purpura (blood blisters in the mouth) and retinal bleeding may also indicate life-threatening bleeding.

**Epidemiology:** ITP is the most common acquired hemorrhaging disorder. It is more common in children than adults. Among children, the prevalence of ITP is similar in girls and boys. A study conducted in Denmark from 1973 to 1995 estimated the annual incidence of ITP among adults at about 22 per million population, taking into account the cut-off point of 50,000 platelets per microliter. Research indicates that the prevalence of ITP among adults is more than 22 per million population. A UK study of all diagnosed cases of ITP between 1990 and 2005 reported a rate of 39 among men and 44 for women (per million).

Since, ITP is a chronic disease in adults, its prevalence is higher than its incidence. A study conducted in the United States on the prevalence of the disease found that the prevalence is about 100 per million population, ranging from 41-160 people per million population (mostly senior citizens).

Approximately 70% of adults with ITP are women (72% under the age of 40). Moreover, in a Danish study, gender differences in the incidence of ITP was only observed in people under 60.

**Clinical symptoms:** Among ITP patients, significant differences in clinical symptoms were observed. Even though the onset of ITP may be acute and sudden, the disease's occurrence is often unclear and latent. Bleeding in symptomatic patients can range from petechiae and bruising to severe, life-threatening hemorrhaging. The proliferation and prevalence of automated blood cell counting devices has led to the detection of asymptomatic

cases with mild thrombocytopenia, expanding the range of ITP clinical symptoms. Clinical symptoms in patients with ITP-induced thrombocytopenia include the following:

- Petshi, purpura and tendency to bruise
- Epistaxis, bleeding gums and menorrhagia
- Severe gastrointestinal bleeding and hematuria (rare)
- Intracranial hemorrhage (uncommon but fatal)

**Diagnosis:** There is no ITP-diagnosis gold standard method. Antibody tests (serological methods) are usually not effective due to their low sensitivity/specificity. Bone marrow assessments can be utilized for older adults (over 60), those with abnormal laboratory symptoms or findings that are not justified/explainable by ITP, or for patients who do not respond to initial treatment. Peripheral blood smears are morphologically normal and may only contain large platelets. Depending on the history of hemorrhaging, iron deficiency anemia may also exist.

Lab tests are conducted to identify ITP's secondary cause and include HIV infection testing, hepatitis C (plus other infections if necessary), serological SLE tests, serum protein electrophoresis and immunoglobulin levels to detect hypogammaglobulinemia or gonadotropin deficiency. In the event of anemia, a direct antiglobulin (Coombs) test is performed to rule out autoimmune hemolytic anemia with ITP (Evans syndrome).

**Treatment:** ITP treatment encapsulates the utilization of medications that reduce the uptake of antibody-bound platelets by the reticuloendothelial system or decreasing antibody production. However, ITP diagnosis does not necessarily translate into prescription of treatment. The risk of thrombocytopenia-related mortality does not increase in patients with platelet counts above 30,000 per microliter. Initial treatment of patients with no symptoms of significant bleeding, severe thrombocytopenia (<5,000 per microliter) and/or symptoms of impending hemorrhaging (such as retinal bleeding or severe bleeding from the oral mucosa) is usually prescribing them some 1 mg kg<sup>-1</sup> prednisone, although immunoglobulin (D) Rho (WinRho SDF) can also be used (dosage: 50-75 1 mg kg<sup>-1</sup>). Rh<sub>0</sub> immunoglobulin (D) should be injected only in +Rh patients since the mechanism of this drug is to create a limited hemolysis and saturation of Fc receptors and inhibition of their function with antibody-coated cells. Upon consumption of this medication, hemoglobin levels are usually reduced (average 1.7 1 mg kg<sup>-1</sup>) and severe intravascular hemolysis is a rare complication. In anemic patients, the dosage should be lowered.

Intravenous gammaglobulin (IvIgG) also blocks Fc receptors in the reticuloendothelial system but appears to

do so via a different mechanism from Rh<sub>0</sub> immunoglobulin (D). In splenectomy patients, IvIgG is more effective than (D) Rh<sub>0</sub>. The total dose is IvIg g kg<sup>-2</sup>, provided in several doses over 2-5 days. Side effects are usually contingent on the volume/quantity of the injection and include aseptic meningitis and kidney failure. All immunoglobulin products are extracted from human plasma and the viral agents in them are removed.

In patients with severe ITP or symptoms of bleeding, hospital admission and a combination therapy approach including high-dose glucocorticoids with IvIg or Rh<sub>0</sub> anti-D and, if necessary, immunosuppressive agents may be prescribed. Rituximab, an anti-CD20 (B cell) antibody, has been demonstrated to be effective in treating resistant ITP.

Splenectomy is utilized to treat patients who develop a recurrent decrease in glucocorticoids. Contrary to popular belief, more patients recover over time but the importance of splenectomy has not diminished. If the platelet count is high enough, monitoring the patient or intermittent treatment with IvIgG or Rh<sub>0</sub> anti-D is a sensible approach to determine if ITP is improving. Prior to splenectomy, vaccination against encapsulated organisms (especially pneumococcus, meningococcus and haemophilus influenzae is recommended depending on the patient's age and possible contacts). Diversionary spleen is a rare cause of the disease's recurrence.

Newer drugs for ITP are thrombopoietin receptor agonists. This treatment stems from the finding that many patients, contrary to previous assumptions, do not have elevated levels of thrombopoietin and do not indicate increased platelet degradation. Two products, one oral and the other subcutaneous, have been demonstrated to be effective in patients with ITP, although their role in ITP treatment is unclear.

**Treatment:** Several treatment regimens have been recommended for the treatment of *H. pylori* infection, Table 1.

Table 1: Treatment regimens for the treatment of *H. pylori* infection

Medication	Dose	Treatment period (weeks)
H2 Antagonist	-	4
Bismuth salicylate	525-mg four times a day	2
Metronidazole	250-mg four times a day	2
Tetracycline	500-mg four times a day	2
Omeprazole	20-mg once daily	4
Clarithromycin	500-mg twice daily	2
Amoxicillin	1000-mg twice daily	2
Omeprazole	20-mg once daily	2
Clarithromycin	500-mg twice daily	2
Metronidazole	500-mg twice daily	2
Omeprazole	20-mg once daily	2
Bismuth	525-mg four times a day	2
Metronidazole	500-mg three times a day	2
Tetracycline	500-mg four times a day	2

Table 2: Research variables

Variables	Background	Disturbance	Independent	Dependent	Quantitative	Qualitative
Platelet count				✓	✓	No. of cells per cubic milliliter
Age	✓				✓	Year
Gender	✓					✓ Male and female
Date since onset of disease	✓				✓	Month
Therapy group			✓			✓ Intervention, control

**Research methodology:** This was an interventional study. The statistical population consisted of all patients diagnosed with immune thrombocytopenic purpura and hospitalized in Kermanshah’s Imam Khomeini Hospital.

**Research environment:** Blood and Oncology Department of Imam Khomeini Hospital, Kermanshah Sampling.

**Permuted-block randomization**

**How sample size was calculated:** Using the comparison formula, 2 means and taking into account the mean and standard deviation from similar studies and 95% confidence and 80% strength in finding the differences between groups, the maximum number required in each group (20 cases) was calculated.

**Data collection method:** Patients with conclusive ITP diagnosis (consistent with the American Hematology Association criteria), examined by an experienced hematologist, hospitalized in Kermanshah’s Imam Khomeini Hospital and met the inclusion and exclusion criteria were included in the study. The diagnosis consisted of condition, physical examination, CBC, peripheral blood smear and bone marrow exam. Pursuant to providing information on how the study would be conducted, all patients were notified regarding the informed written consent for participation in the study. Demographic data of patients (including age, sex and duration of disease onset) was recorded in a questionnaire. Stool samples were taken from all patients for evaluation (regarding presence of *H. pylori* antigen). Patients who tested negative for fecal antigen were excluded from the study. The patients were divided into intervention and control groups utilizing permuted-block randomization (blocks of 4 and 6). The research was a double-blind study and the patients and the medical individual in charge of the patients were all from the treatment group. In the intervention group, *H. pylori* eradication regimen contained the following prescribed medications:

- Clarythromycin 500 mg BD N = 28
- Amoxicilin 1 g BD N = 28
- Omeprazol 20 mg BD N = 90

The control group received the same placebo in terms of number and shape as the case group. At the end of the treatment period, the patients underwent fecal

examination again to ensure *H. pylori* had been eradicated. During the treatment period, platelet count was monitored three times (intervals of one, two and three months) and if the platelet count increased before the end of the treatment period, the individual would be excluded from the study (and considered as spontaneous improvement). The impact of treatment was evaluated consistent with the platelet count.

**Inclusion and exclusion criteria**

**Inclusion criteria:**

- ITP diagnosis (compliant with the criteria of the American Hematology Association, plus examination by an experienced hematologist
- Platelet count between 30 and 150 thousand
- Non-wet purpura
- Non life-threatening bleeding/hemorrhage
- *H. pylori* antigen stool positive test

**Exclusion criteria:**

- History of allergy to penicillin
- Irregular medication use by the patient
- Malabsorption related diseases

**Data description and analysis method:** The data obtained from this study were statistically analyzed via utilizing the SPSS Software (Version 16. Chi-Square, Independent T-test and repeated measures. The significance level of P was considered <0.05 (Table 2).

**RESULTS AND DISCUSSION**

In this study, 40 patients with immune thrombocytopenic purpura (in intervention and control groups) were treated with *H. pylori* eradication. The mean age of the patients was 34.82±9.06 years (35.2±9.64 in the intervention group and 34.45±8.68 in the control group, p = 0.8) (Table 3).

According to the above table, 50% of the patients in the intervention group and 70% of the patients in the control group were male. The two groups were in a similar situation in terms of gender (p = 0.2) (Table 4).

The mean duration of immune thrombocytopenic purpura in all patients was 20.45±11.14 months (median of 23 months), 18.45±12.46 months in the intervention group and 22.45±9.45 months in the control group. The

Table 3: Frequency of study patients by gender

Gender	Group intervention	Group control	Total
Male	10	14	24
Female	10	6	16
Total	20	20	40
p-value	0.2*2	20	40

Table 4: Comparison of disease duration in the study groups

Group	Quantity	Mean	SD	p-value
Intervention	20	18.45	12.66	0.26
Control	20	22.45	9.67	0.26

Table 5: Mean platelet count comparison prior to intervention

Group	Quantity	Mean	SD	p-value
Intervention	20	67750	19770	0.82
Control	20	69950	23685	0.82

Table 6: Mean platelet count comparison in the first, second and third months after treatment

Time (month)	Group	Mean	SD	p-value
1st	Intervention	74200	20255	0.70
1st	Control	71550	23520	0.70
2nd	Intervention	88600	27660	0.03
2nd	Control	71350	21947	0.03
3rd	Intervention	107150	31843	<0.001
3rd	Control	71150	20171	<0.001




Fig. 1: Comparison of mean scores of depression during treatment in the two treatment groups

difference between the two groups was not statistically significant ( $p = 0.26$ ) (Table 5).

Comparison of the mean platelet count before the intervention in the study groups revealed that the two groups were in a similar position in terms of platelet count ( $p = 0.82$ ) (Table 6).

Compliant to the findings of the above table, it was discovered that the mean platelet count in the first month after treatment was similar in the two groups, while in the second and third months after treatment, the mean in the intervention group was significantly higher than the control group (Fig. 1).

Repeated measures analysis of platelet count at various times of the study demonstrated that the two groups were different in terms of platelet count changes

( $p = 0.007$ ), specifically, the intervention group had superior results compared to the control group in all stages of the study.

## CONCLUSION

This study was performed to assess the effects of *H. pylori* eradication treatment on platelet count in patients with immune thrombocytopenic purpura. The findings revealed that elimination of *H. pylori* significantly increases the number of platelets in patients.

Various research in this field have had disparate results in different geographical areas. In a Zccrdance with the findings of our research, a study conducted by Kohda & Associates discovered that 62.5% of ITP patients were infected with helicobacter pylori. Pursuant to being treated (via eradication), the platelet counts in more than 63.2% of patients showed a significant increase, up to 15 months after treatment<sup>[20]</sup>. Hino AND Associates reported *H. pylori* infection in 85.7% of ITP patients and eradication treatment being successful in more than 55% of patients. Analysis of patients revealed that with the elimination of the infection, platelet count increased significantly in the months following<sup>[18]</sup>. This is similar to our present study as well as findings from other research heretofore alluded to<sup>[19,28,31,32,41-44]</sup>.

In contrast to the above studies, a number of researches have pointed to the ineffectiveness of *H. pylori* eradication treatment in increasing platelet count. Jarque and Associates, by examining the impact of *H. pylori* eradication on platelet count in patients with chronic ITP, found that only 5% of them had increased platelet count following treatment for helicobacter pylori<sup>[40]</sup>. In a study conducted by Payandeh and Associates on 92 ITP patients in Iran, it was discovered that eradication of *H. pylori* infection significantly improved platelet count in mild ITP patients, when prescribed the three drugs, amoxicillin, clarithromycin and omeprazole,. However, in patients with severe ITP this treatment had little effect on platelet count<sup>[41]</sup>. This discrepancy has been delineated in other studies as well.

Even though the number and quality of studies pointing to the positive role of *H. pylori* elimination within the course of ITP treatment is higher but the observed discrepancy can be justified in some ways. Pathogenic differences in various strains of *H. pylori* are among the most important possible causes of the existing conflict. Studies have shown that *H. pylori* genotypes have significant differences in the development of gastrointestinal symptoms<sup>[42,43]</sup>. Although it is not clear to what extent bacterial genotypic differences are involved in the development of extra-gastrointestinal symptoms, the geographical dispersion of the positive findings of studies suggests the effect of these differences. Most of the studies mentioned earlier (confirming the positive



effect of *H. pylori* eradication on platelet count) have been performed in East Asia and the majority of studies with negative results were in Europe and the Americas<sup>[2,23,40]</sup>. Even though a review of the regional differences has been studied, it is difficult to draw conclusions due to the lack of sufficient data concerning the infectious strains of ITP patients<sup>[44]</sup>.

Another possible factor in the assorted responses of ITP patients to *H. pylori* infection treatment is the disease's duration. In a limited number of studies in this field, the ITP duration is noted. Comparison of mean platelet count changes after eradication of *H. pylori* indicates that platelet counts are higher in patients with shorter disease duration than in chronic ITP patients<sup>[25,32,33,41,42,43]</sup>. Further studies in this area and meta-analysis of the findings shall be helpful in better understanding this relationship.

The infection duration and how the *H. pylori* infection develops in patients is another possible factor that can affect the response to eradication treatment. Various mechanisms have been proposed to explicate the role of *H. pylori* in the creation and/or exacerbation of ITP, such as antibody production, Von Willebrand factor interference, B lymphocyte activation, increased phagocytic activity of monocytes, etc.<sup>[33]</sup>. It appears that eradication treatment prior to establishing the alluded to immunological processes, increases the success of controlling the course of platelet depletion. It was difficult/challenging to examine and test this factor due to the existing limitations.

Even though the etiological role of *H. pylori* in ITP's pathogenesis has been established, one should bear in mind that other factors such as viral infections (HIV, CMV and VZV) and immune system disorders have also been implicated in the pathogenesis of this disease<sup>[52-54]</sup>. The interaction of these factors can also be impactful in response to any type of treatment, including *H. pylori* eradication treatment.

Among the present study's constraints was its small sample size, due to the challenge and difficulty of finding patients with the right conditions (this limitation also existed in previous studies). The lack of possibility of performing endoscopy as well as the inability to directly study *H. pylori* (due to condition of patients) was another limitation of the study, making it impossible to utilize a method with high sensitivity and specificity to check and verify the presence and thereafter elimination of *H. pylori*.

## REFERENCES

1. Adiloglu, A.K., A.Ocal, R. Can, H. Duver, T. Yavuz and B.C. Aridogan, 2005. Detection of Helicobacter pylori and Chlamydia pneumoniae DNA in human coronary arteries and evaluation of the results with serologic evidence of inflammation. Saudi. Med. J., 26: 1068-1074.
2. Arebestani, M.A., M.Y. Alikhani, M.S. Khorasani, A. Majlesi and M. Jaefari, 2014. Evaluation of Helicobacter pylori vacA and cagA Genotypes and Correlation With Clinical Outcome in Patients With Dyspepsia in Hamadan Province, Iran. Iran. Red. Crescent Med. J., 10.5812/ircmj.19173
3. Ando, L., T. Shimamoto, T. Tauchi, Y. Ito and Y. Kuriyama *et al.*, 2003. Can eradication therapy for helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? our experience and a literature review. Int. J. Hematol., 77: 239-244.
4. Ando, T., T. Tsuzuki, T. Mizuno, M. Minami and K. Ina *et al.*, 2004. Characteristics of Helicobacter pylori-Induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter, 9: 443-452.
5. Asahi, A., T. Nishimoto, Y. Okazaki, H. Suzuki, T. Masaoka *et al.*, 2008. Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγgammaRIIB in immune thrombocytopenic purpura patients. J. Clin. Invest., 118: 2939-2949.
6. Banatvala, N., K. Mayo, F. Megraud, R. Jennings, J.J. Deeks and R.A. Feldman, 1993. The cohort effect and Helicobacter pylori. J. Infect. Dis., 168: 219-221.
7. British Committee for Standards in Haematology General Haematology Task Force, 2003. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br. J. Haematol., 120: 574-596.
8. Byrne, M.F., S.W. Kerrigan, P.A. Corcoran, J.C. Atherton, F.E. Murray, D.J. Fitzgerald and D.M. Cox, 2003. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterol., 124: 1846-1854.
9. Maya, G.C., 2007. Proof of an Association between Helicobacter pylori and Idiopathic thrombocytopenic Purpura in Latin America. Helicobacter, 12: 265-273.
10. Cines, D.B., H. Liebman and R. Stasi, 2009. Pathobiology of Secondary Immune Thrombocytopenia. Semin. Hematol., 46: S2-S14.
11. Danesh, J., L. Youngman, S. Clark, S. Parish, R. Peto and R. Collins, 1999. Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. BMJ, 319: 1157-1162.
12. DiMaggio, D., A. Anderson and J.B. Bussel, 2009. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br. J. Haematol., 146: 104-112.
13. Emilia, G., G. Longo, M. Luppi, G. Gandini and M. Morselli *et al.*, 2001. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood, 97: 812-814.

14. Emilia, G., M. Luppi and G. Torelli, 2005. Infectious agents and human immune diseases: Lessons from *Helicobacter pylori*. American J. Med., 118: 420-421
15. Emilia, G., M. Luppi, P. Zucchini, M. Morselli and L. Potenza *et al.*, 2007. *Helicobacter pylori* infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood, 110: 3833-3841.
16. Franchini, M and D. Veneri, 2006. *Helicobacter pylori*-associated immune thrombocytopenia. Platelets, 17: 71-77.
17. Franchini, M., 2005. Thrombotic thrombocytopenic purpura: Proposal of a new pathogenic mechanism involving *Helicobacter pylori* infection. Med. Hypotheses, 65: 1128-1131.
18. Frydman, G.H., N. Davis, P.L. Beck and J.G. Fox, 2015. *Helicobacter pylori* Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography. Helicobacter, 20: 239-251.
19. Fujimura, K., M. Kuwana, Y. Kurata, M. Imamura and H. Harada *et al.*, 2005. Is Eradication Therapy Useful as the First Line of Treatment in *Helicobacter pylori*-Positive Idiopathic Thrombocytopenic Purpura? Analysis of 207 Eradicated Chronic ITP Cases in Japan. Int. J. Hematol., 81: 162-168.
20. Gan, G.G., A.L. Norfaizal, P.C. Bee, E.F.M. Chin, A.H. Habibah and K.L. Goh, 2013. *Helicobacter pylori* infection in chronic immune thrombocytopenic purpura patients in Malaysia. Med. J. Malaysia., 68: 231-233.
21. Gasbarrini, A., F. Franceschi, R. Tartaglione, R. Landolfi, P. Pola and G. Gasbarrini, 1998. Regression of autoimmune thrombocytopenia after eradication of *Helicobacter pylori*. Lancet, 10.1016/S0140-6736(05)60004-9
22. Gasbarrini, A and F. Franceschi, 2005. Does *H. pylori* infection play a role in idiopathic thrombocytopenic purpura and in other autoimmune diseases? Am. J. Gastroenterol., 100: 1271-1273.
23. Safaei, H.G., E. Rahimi, A. Zandi and A. Rashidipour, 2011. *Helicobacter pylori* as a zoonotic infection: the detection of *H. pylori* antigens in the milk and faeces of cows. J. Res. Med. Sci., 16: pp; 184-187.
24. Gunn, G., J.C. Stephens, J.R. Thompson, B.J. Rathbone and N.J. Samani, 2000. Significant association of *cagA* positive *Helicobacter pylori* strains with risk of premature myocardial infarction. Heart, 84: 267-271.
25. Hashino, S., A. Mori, S. Suzuki, K. Izumiyama and K. Kahata *et al.*, 2003. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of *Helicobacter pylori*. Int. J. Hematol., 77: 188-191.
26. Hino, M., T. Yamane, K. Park, T. Takubo and K. Ohta *et al.*, 2003. Platelet recovery after eradication of *Helicobacter pylori* in patients with idiopathic thrombocytopenic purpura. Ann. Hematol., 82: 30-32.
27. Inaba, T., M. Mizuno, S. Take, K. Suwaki and T. Honda *et al.*, 2005. Eradication of *Helicobacter pylori* increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur. J. Clin. Invest., 35: pp; 214-219.
28. Jackson, S., P.L. Beck, G.F. Pineo and M.C. Poon, 2005. *Helicobacter pylori* eradication: Novel therapy for immune thrombocytopenic purpura? A review of the literature. Am. J. Hematol., 78: 142-150.
29. Jarque, I., R. Andreu, I. Llopis, J. De la Rubia and F. Gomis *et al.*, 2001. Absence of platelet response after eradication of *Helicobacter pylori* infection in patients with chronic idiopathic thrombocytopenic purpura. Br. J. Haematol., 115: 1002-1003.
30. Kohda, K., T. Kuga, K. Kogawa, Y. Kanisawa and K. Koike *et al.*, 2002. What Is New Related to *Helicobacter pylori* Infection in Children and Teenagers? Arch. Pediatr. Adolesc. Med., 159: 415-421.
31. Kohda, K., T. Kuga, K. Kogawa, Y. Kanisawa and K. Koike *et al.*, 2003. Effect of *Helicobacter pylori* eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br. J. Haematol., 118: 584-588.
32. Kuwana, M and Y. Ikeda, 2006. *Helicobacter pylori* and immune thrombocytopenic purpura: unsolved questions and controversies. Int. J. Hematol., 84: 309-315.
33. Latsios, G., A. Saetta, N.V. Michalopoulos, E. Agapitos and E. Patsouris, 2004. Detection of cytomegalovirus, *Helicobacter pylori* and Chlamydia pneumoniae DNA in carotid atherosclerotic plaques by the polymerase chain reaction. Acta. Cardiol., 59: 652-657.
34. Liebman, H.A and R. Stasi, 2007. Secondary immune thrombocytopenic purpura. Curr. Opin. Hematol., 14: 557-573.
35. Mahévas, M., L. Chiche, Y. Uzunhan, M. Khellaf and A.S. Morin *et al.*, 2011. Association of sarcoidosis and immune thrombocytopenia: presentation and outcome in a series of 20 patients. Med., 90: 269-278.

36. Malfertheiner, P., F. Megraud, C. O'Morain, F. Bazzoli and E.E. Omar *et al.*, 2007. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut.*, 56: 772-781.
37. Ghanaei, F.M., M.Y. Mashhour, F. Joukar, M. Sedigh, A.H. Bagherzadeh and R. Jafarshad, 2009. Prevalence Of *Helicobacter Pylori* Infection Among Children In Rasht, Northern Iran. *Middle East J. Digestive Dis.*, 1: 84-88.
38. Massarrat, S., M. Saberi-Firoozi, A. Soleimani, G.W. Himmelmann, M. Hitzges and H. Keshavarz, 1995. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. *Eur. J. Gastroenterol. Hepatol.*, 7: 427-433.
39. Michel, M., N. Cooper, C. Jean, C. Frizzera and J.B. Bussel, 2004. Does *Helicobacter pylori* initiate or perpetuate immune thrombocytopenic purpura? *Blood*, 103: 890-896.
40. Nomura, S., N. Inami and S. Kanazawa, 2004. The effects of *Helicobacter pylori* eradication on chemokine production in patients with immune thrombocytopenic purpura. *Eur. J. Haematol.*, 72: 304-305.
41. Payandeh, M., D. Raeesi, N. Sohrabi, M.E. Zare and A.N. Kansestani *et al.*, 2013. Poor platelet Count Response to *Helicobacter Pylori* Eradication in Patients with Severe Idiopathic Thrombocytopenic Purpura. *Int. J. Hematol. Oncol. Stem Cell Res.*, 7: 9-14.
42. Pellicano, R., M.G. Mazzarello, S. Morelloni, Ilegri M. A and V. Arena *et al.*, 1999. Acute myocardial infarction and *Helicobacter pylori* seropositivity. *Int. J. Clin. Lab. Res.*, 29: 141-144.
43. Perez-Perez, G.I., A. Salomaa, T.U. Kosunen, B. Daverman, H. Rautelin, A. Aromaa, P. Knekt and M.J. Blaser, 2002. Evidence that cagA(+) *Helicobacter pylori* strains are disappearing more rapidly than cagA(-) strains. *Gut*, 50: 295-298.
44. Pietrojusti, A., M. Diomed, M. Silvestrini, L.M. Cupini and I. Luzzi *et al.*, 2002. Cytotoxin-Associated Gene-A—Positive *Helicobacter pylori* Strains Are Associated With Atherosclerotic Stroke. *Circulation*, 106: 580-584.
45. Roark, J.H., J.B. Bussel, D.B. Cines and D.L. Siegel, 2002. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. *Blood*, 100: 1388-1398.
46. Rostami, N., M.K. Jahromi, M. Rahnavardi, M.K. Jahromi and F.S. Esfahani, 2008. Effect of eradication of *Helicobacter pylori* on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: A controlled trial. *Am. J. Hematol.*, 83: 376-381.
47. Hosseini, S. and M.B. Khamesee, 2021. Modeling and simulation and imaging of blood flow in the human body. *Nat. Volatiles Essent. OILS-NVEO.*,
48. Hosseini, S. and B. Khamesee, 2017. BIO-03 design and control of a magnetically driven capsule-robot for endoscopy (bio-medical equipments i, technical program of oral presentations). *Proceedings of the JSME-IIP/ASME-ISPS Joint Conference on Micromechatronics for Information and Precision Equipment*, June 7-20, 2009, Japan Society of Mechanical Engineers, Jbaraki, Japan, 219-220.
49. Hosseini, S and M.B. Khamesee, 2009. Design and control of a magnetically driven capsule-robot for endoscopy and drug delivery. *Proceedings of the 2009 International Conference Science and Technology for Humanity (TIC-STH)*, September 26-27, 2009, IEEE, Toronto, Canada, pp; 697-702.
50. Hosseini, S and M.B. Khamesee, 2021. Evaluation of Splint Effect on the Dimensional Variations of Implants Location Transfer with a 25° Angle by Open Tray Molding Method. *Res. J. Med. Sci.*, 15: 83-93.
51. Hosseini, S., M. Mehrtash and M.B. Khamesee, 2011. Design, fabrication and control of a magnetic capsule-robot for the human esophagus. *Microsyst. Technol.*, 17: 1145-1152.
52. Sato, R., K. Murakami, K. Watanabe, T. Okimoto and H. Miyajima *et al.*, 2004. Effect of *Helicobacter pylori* Eradication on Platelet Recovery in Patients With Chronic Idiopathic Thrombocytopenic Purpura. *Arch. Intern. Med.*, 164: 1904-1907.
53. Sherman, P.M., 2004. Appropriate strategies for testing and treating *Helicobacter pylori* in children: When and how? *Am. J. Med.*, 117: 30-35.
54. Stasi, R., Z. Rossi, E. Stipa, S. Amadori, A.C. Newland and D. Provan, 2005. *Helicobacter pylori* eradication in the management of patients with idiopathic thrombocytopenic purpura. *Am. J. Med.*, 118: 414-419.
55. Stasi, R., A. Sarpatwari, J.B. Segal, J. Osborn and M.L. Evangelista *et al.*, 2009. Effects of eradication of *Helicobacter pylori* infection in patients with immune thrombocytopenic purpura: a systematic review. *Blood*, 113: 1231-1240.
56. Suerbaum, S. and P. Michetti, 2002. *Helicobacter pylori* infection. *N. Engl. J. Med.*, 347: 1175-1186.
57. Suvajdžić, N., B. Stanković, V. Artiko, T. Cvejić and V. Bulat *et al.*, 2006. *Helicobacter pylori* eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. *Platelets*, 17: 227-230.
58. Suzuki, T., M. Matsushima, A. Masui, K. Watanabe and A. Takagi *et al.*, 2005. Effect of *Helicobacter pylori* eradication in patients with chronic idiopathic thrombocytopenic purpura—a randomized controlled trial. *Am. J. Gastroenterology*, 100: 1265-1270.



59. Tag, H.S., H.S. Lee, S.H. Jung, B.K. Kim and S.B. Kim *et al.*, 2010. Effects of *Helicobacter pylori* eradication in patients with immune thrombocytopenic purpura. *Korean J. Hematol.*, 45: 127-132.
60. Takahashi, T., T. Yujiri, K. Shinohara, Y. Inoue and Y. Sato *et al.*, 2004. Molecular mimicry by *Helicobacter pylori* CagA protein may be involved in the pathogenesis of *H. pylori*-associated chronic idiopathic thrombocytopenic purpura. *Br. J. Haematol.*, 124: 91-96.
61. Trujillo, E., T. Martínez and M.M. Bravo, 2014. [Genotyping of *Helicobacter pylori* virulence factors *vacA* and *cagA* in individuals from two regions in Colombia with opposing risk for gastric cancer]. *Biomedica.*, 34: 567-573.
62. Veneri, D., M. Franchini, M. Gottardi, M.D. Adda and A. Ambrosetti *et al.*, 2002. Efficacy of *Helicobacter pylori* eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. *Haematologica*, 87: 1177-1179.
63. Veneri, D., M. Krampera and M. Franchini, 2005. High prevalence of sustained remission of idiopathic thrombocytopenic purpura after *Helicobacter pylori* eradication: A long-term follow-up study. *Platelets*, 16: 117-119.